4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine and 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine derivatives as PDE1 Inhibitors
LI, PENG,ZENG, HAILIN,ZHAO, JUN,WENNOGLE, LAWRENCE, P
申请号：
NZ59303309
公开号：
NZ593033A
申请日:
2009.12.07
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
593033 Disclosed are substituted imidazo[1,2-a]pyrrolo[4,3-e]pyrimidine compounds of formula II-A or formula II-B (I) where the substituents are as disclosed in the specification. Examples of a compounds of formula (I) are: (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-2-(4-(6-fluoropyridin-2-yl)benzyl)cyclopent[4,5]imidazo[1,2-a]pyrrolo[4,3-e]pyrimidin-4(2H)-one and (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-1,5-dimethyl-2-(4-(6-fluoropyridin-2-yl)benzyl)-cyclopent[4,5] imidazo[1,2-a]pyrrolo[4,3-e]pyrimidin-4(2H)-one. Also disclosed are pharmaceutical compositions comprising a compound of formula II-A or II-B the use of a compound of formula II-A or II-B in the manufacture of a medicament. The medicament is useful in the treatment of glaucoma or elevated intraocular pressure, psychosis, schizophrenia, schizo affective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, and mania, such as in acute manic episodes and bipolar disorder, traumatic brain injury, lengthening or enhancing growth of the eyelashes.
